FDA approves pricy new treatment for Alzheimer's: What you need to know
(WGN Radio) – A new drug that shows promising results of slowing memory decline recently received the
The FDA endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease. It works by clearing a sticky brain plaque linked to the disease, and it's the first medicine that's been convincingly shown to modestly slow the cognitive decline caused by Alzheimer's.
But Leqembi doesn't come cheap. It is priced at about
"If we had to pay out of pocket, you'd certainly have to have substantial funds to do this," said Dr.
But the recent FDA approval paves the way for Medicare and other insurers to cover the drug.
Medicare administrator,
"I look at it and say it's our opportunity to prove that the drug is really working well. It will advance the other five, six, seven drugs that are in the pipeline right now that are doing similar things to remove that beta amyloid from the brain," said
Even ignoring cost or insurance coverage, not every person with Alzheimer's will be able to get their hands on the drug. Doctors will need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it.
"When you look at the 6.5 million people with Alzheimer's, it's going to come down to a classification of probably between 1 to 2 million individuals will be available – or will be allowed – to do it," said
Leqembi's drugmaker
Hear more from
The Associated Press contributed to this report.


Fight over gender-affirming care moves to HHS spending bill
Ron DeSantis keeps explaining away old Social Security, Medicare stances
Advisor News
- Survey: Most Americans still feel prosperous despite economic worries
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
More Annuity NewsHealth/Employee Benefits News
- EXPLORING INSULIN COST-SHARING CAPS FOR PATIENTS WITH PRIVATE COVERAGE
- THE AMERICAN DIABETES ASSOCIATION FIGHTS TO MAINTAIN ACCESS TO HEALTH INSURANCE
- Grand jury accuses veteran of making false disability claims that defrauded VA
- States push short-term insurance as healthcare costs climb
- Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
More Health/Employee Benefits NewsLife Insurance News
- FORMER PRINCE GEORGE'S COUNTY INSURANCE AGENT SENTENCED FOR FELONY INSURANCE THEFT SCHEME
- AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
- AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
More Life Insurance News